Sinovac Biotech Ltd banner

Sinovac Biotech Ltd
NASDAQ:SVA

Watchlist Manager
Sinovac Biotech Ltd Logo
Sinovac Biotech Ltd
NASDAQ:SVA
Watchlist
Price: 6.47 USD Market Closed
Market Cap: $644.7m

Wall Street
Price Targets

SVA Price Targets Summary
Sinovac Biotech Ltd

There are no price targets for SVA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Sinovac Biotech Ltd Competitors:
Price Targets
STG
Strip Tinning Holdings PLC
168% Upside
LAND
Gladstone Land Corp
-1% Downside
NSIT
Insight Enterprises Inc
74% Upside
HCAT
Health Catalyst Inc
227% Upside
VAC
Pierre et Vacances SA
35% Upside

Revenue
Forecast

22% / Year
Past Growth
-20% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat
22% / Year
Past Growth
-20% / Year
Estimated Growth
Estimates Accuracy
2%
Average Beat

For the last 13 years the compound annual growth rate for Sinovac Biotech Ltd's revenue is 22%. The projected CAGR for the next 9 years is -20%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-34%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-34%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SVA's stock price target?
Not Available

SVA doesn't have any price targets made by Wall Street professionals.

What is Sinovac Biotech Ltd's Revenue forecast?
Projected CAGR
-20%

For the last 13 years the compound annual growth rate for Sinovac Biotech Ltd's revenue is 22%. The projected CAGR for the next 9 years is -20%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett